Predictive factors for the clinical effect of PD-1/PD-L1 checkpoint inhibitors in treatment of hepatocellular carcinoma
10.3969/j.issn.1001-5256.2020.06.044
- VernacularTitle:程序性细胞死亡蛋白1及其配体抑制剂治疗肝细胞癌效果的预测因素
- Author:
Fushuang HA
1
;
Tao HAN
;
Fei TANG
;
Junqing YAN
;
Haoyu WANG
Author Information
1. Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, Tianjin 300170, China)
- Publication Type:Research Article
- Keywords:
carcinoma, hepatocellular;
programmed cell death protein 1;
treatment outcome;
predictors
- From:
Journal of Clinical Hepatology
2020;36(6):1389-1392
- CountryChina
- Language:Chinese
-
Abstract:
At present, there is still a lack of uniform treatment strategies for hepatocellular carcinoma (HCC). Immunotherapy, especially PD-1/PD-L1 checkpoint inhibitors, is a novel therapy for HCC and can bring survival benefits to patients with advanced HCC. However, research data show that only a small number of HCC patients can benefit from this treatment regimen. To date, few biomarkers have been reported to predict the clinical effect of PD-1/PD-L1 checkpoint inhibitors in HCC patients. This article reviews the biomarkers studied for HCC and other tumors and explores the possible predictive factors for the clinical effect of PD-1/PD-L1 checkpoint inhibitors in HCC, in order to optimize the selection of treatment population and improve the clinical effect of PD-1/PD-L1 checkpoint inhibitors in the treatment of HCC.
